Artwork

Sisällön tarjoaa Anuj Desai. Anuj Desai tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Player FM - Podcast-sovellus
Siirry offline-tilaan Player FM avulla!

EPISODE #161 Cannabis Vs. Opioids with Valentino Parravicini, Chief Scientific Officer at Oxford Cannabinoid Technologies

43:00
 
Jaa
 

Manage episode 328711290 series 2522512
Sisällön tarjoaa Anuj Desai. Anuj Desai tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.

This week, we’re joined by Valentino Parravicini, Chief Scientific Officer at Oxford Cannabinoid Technologies - British pharmaceutical company developing a portfolio of next-generation prescription cannabinoid medicines.

In this episode, we explore the potential use of cannabis-based medicines as a replacement for prescription opioids, their safety profile, and their use cases as analgesics.

📚 VIEW SHOW NOTES AND EXTRAS:

https://www.canverse.global/shownotes/e161

About Valentino Parravicini

Valentino has spent his academic career at the NIH (NIAMS-USA) working in allergy and inflammation and discovering a new signalling pathway in mast cells. After moving to the National Institute for Medical Research, Mill Hill (NIMR, now part of the Francis Crick), he focussed on animal models of inflammation and autoimmunity. He has been Visiting Scientist at Imperial College London and King’s College London.

Valentino has over 12 years of experience in drug discovery and development accrued working in Big Pharma and SMEs. He worked at Roche (Italy), and at the Epigenetic Drug Performance Unit of the Immune-Inflammation Therapeutic Area of GlaxoSmithKline (GSK, UK).

He was also involved in the set-up of two start-up biotechnology companies, first at Kesios Therapeutics (oncology), and the at GammaDelta Therapeutics (cell and gene therapy in oncology), which was recently acquired by Takeda. He has lead research teams and programmes in the fields of immune-inflammation, oncology, and virology, both in small molecules and cell therapy, applied to early research and drug discovery and development.

He most recently joined Oxford Cannabinoid Technologies as Chief Scientific Officer where he contributed to shaping the cannabinoid-based R&D pipeline and overall scientific strategy leading to the Company’s IPO in May 2021.

Resources

Join Valentino on Linkedin: https://www.linkedin.com/in/valentino-parravicini/?originalSubdomain=uk

Follow Oxford Cannabinoid Technologies on Linkedin: https://www.linkedin.com/company/oxford-cannabinoid-technologies/

Oxford Cannabinoid Technologies Website: https://www.oxcantech.com/

  continue reading

194 jaksoa

Artwork
iconJaa
 
Manage episode 328711290 series 2522512
Sisällön tarjoaa Anuj Desai. Anuj Desai tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.

This week, we’re joined by Valentino Parravicini, Chief Scientific Officer at Oxford Cannabinoid Technologies - British pharmaceutical company developing a portfolio of next-generation prescription cannabinoid medicines.

In this episode, we explore the potential use of cannabis-based medicines as a replacement for prescription opioids, their safety profile, and their use cases as analgesics.

📚 VIEW SHOW NOTES AND EXTRAS:

https://www.canverse.global/shownotes/e161

About Valentino Parravicini

Valentino has spent his academic career at the NIH (NIAMS-USA) working in allergy and inflammation and discovering a new signalling pathway in mast cells. After moving to the National Institute for Medical Research, Mill Hill (NIMR, now part of the Francis Crick), he focussed on animal models of inflammation and autoimmunity. He has been Visiting Scientist at Imperial College London and King’s College London.

Valentino has over 12 years of experience in drug discovery and development accrued working in Big Pharma and SMEs. He worked at Roche (Italy), and at the Epigenetic Drug Performance Unit of the Immune-Inflammation Therapeutic Area of GlaxoSmithKline (GSK, UK).

He was also involved in the set-up of two start-up biotechnology companies, first at Kesios Therapeutics (oncology), and the at GammaDelta Therapeutics (cell and gene therapy in oncology), which was recently acquired by Takeda. He has lead research teams and programmes in the fields of immune-inflammation, oncology, and virology, both in small molecules and cell therapy, applied to early research and drug discovery and development.

He most recently joined Oxford Cannabinoid Technologies as Chief Scientific Officer where he contributed to shaping the cannabinoid-based R&D pipeline and overall scientific strategy leading to the Company’s IPO in May 2021.

Resources

Join Valentino on Linkedin: https://www.linkedin.com/in/valentino-parravicini/?originalSubdomain=uk

Follow Oxford Cannabinoid Technologies on Linkedin: https://www.linkedin.com/company/oxford-cannabinoid-technologies/

Oxford Cannabinoid Technologies Website: https://www.oxcantech.com/

  continue reading

194 jaksoa

Kaikki jaksot

×
 
Loading …

Tervetuloa Player FM:n!

Player FM skannaa verkkoa löytääkseen korkealaatuisia podcasteja, joista voit nauttia juuri nyt. Se on paras podcast-sovellus ja toimii Androidilla, iPhonela, ja verkossa. Rekisteröidy sykronoidaksesi tilaukset laitteiden välillä.

 

Pikakäyttöopas